Six details:
1. Full-year 2020 net sales are expected to be $407 million, representing a 12 percent decrease year over year.
2. For the fourth quarter, spinal implants net sales increased 11 percent, to $28 million, and biologics sales decreased 9 percent to $15 million, compared to the same period in 2019.
3. Orthofix attributed the rise in spinal implants sales to the adoption of its M6-C artificial cervical disc.
4. Motion preservation net sales in the fourth quarter are expected to rise 129 percent year over year to $7 million.
5. As of Dec. 31, cash, cash equivalents, and restricted cash was $96 million to $97 million, compared to $70 million on Dec. 31, 2019.
6. Orthofix will report full-year 2020 financial results and provide its financial outlook for 2021 in late February.
More articles on devices:
Medtronic CEO predicts AI, machine learning as ‘the new frontier for medtech’ — 4 key quotes
40 orthopedic devices receiving FDA clearance in December
Stryker, Smith+Nephew seal 1st acquisitions of 2021: 7 device company notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
